Advanced

Management of bleeding disorders in children

Berntorp, Erik LU ; Halimeh, S.; Gringeri, A.; Mathias, M.; Escuriola, C. and Perez, R. (2012) In Haemophilia 18(Suppl. 2). p.15-23
Abstract
Haemophilia, if not properly managed, can lead to chronic disease and lifelong disabilities. The challenges and issues in infants/young children are different from those in older children and adults although episodes of bleeding still predominate as the diagnostic trigger. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitor development is a challenging complication of paediatric haemophilia and prophylaxis is emerging as the optimal preventive care strategy. In this section we will review some important aspects of haemophilia in children including early prophylaxis, current evidence relating to inhibitor development,... (More)
Haemophilia, if not properly managed, can lead to chronic disease and lifelong disabilities. The challenges and issues in infants/young children are different from those in older children and adults although episodes of bleeding still predominate as the diagnostic trigger. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitor development is a challenging complication of paediatric haemophilia and prophylaxis is emerging as the optimal preventive care strategy. In this section we will review some important aspects of haemophilia in children including early prophylaxis, current evidence relating to inhibitor development, including the aims of the SIPPET study which is already ongoing and involves boys <6 years, and the potential of immune tolerance therapy for eradicating the inhibitor and permitting a resumption of standard dosing schedules. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Blood Coagulation Factor Inhibitors: immunology Factor VIII: administration & dosage Factor VIII: therapeutic use Hemophilia A: drug therapy Hemophilia A: immunology
in
Haemophilia
volume
18
issue
Suppl. 2
pages
15 - 23
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000303155600004
  • scopus:84860305819
ISSN
1351-8216
DOI
10.1111/j.1365-2516.2012.02796.x
language
English
LU publication?
yes
id
7655060b-91d8-446e-ac23-b242cb956847 (old id 2563227)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22530575?dopt=Abstract
date added to LUP
2012-06-01 08:48:27
date last changed
2017-01-01 03:08:01
@article{7655060b-91d8-446e-ac23-b242cb956847,
  abstract     = {Haemophilia, if not properly managed, can lead to chronic disease and lifelong disabilities. The challenges and issues in infants/young children are different from those in older children and adults although episodes of bleeding still predominate as the diagnostic trigger. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitor development is a challenging complication of paediatric haemophilia and prophylaxis is emerging as the optimal preventive care strategy. In this section we will review some important aspects of haemophilia in children including early prophylaxis, current evidence relating to inhibitor development, including the aims of the SIPPET study which is already ongoing and involves boys &lt;6 years, and the potential of immune tolerance therapy for eradicating the inhibitor and permitting a resumption of standard dosing schedules.},
  author       = {Berntorp, Erik and Halimeh, S. and Gringeri, A. and Mathias, M. and Escuriola, C. and Perez, R.},
  issn         = {1351-8216},
  keyword      = {Blood Coagulation Factor Inhibitors: immunology Factor VIII: administration & dosage Factor VIII: therapeutic use Hemophilia A: drug therapy Hemophilia A: immunology},
  language     = {eng},
  number       = {Suppl. 2},
  pages        = {15--23},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {Management of bleeding disorders in children},
  url          = {http://dx.doi.org/10.1111/j.1365-2516.2012.02796.x},
  volume       = {18},
  year         = {2012},
}